Theranos CEO Banned from Running Labs for Two Years

Federal regulators also revoked a certificate for the company’s Newark, California lab.

Written byTanya Lewis
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Elizabeth HolmesWIKIMEDIA, GLENN FAWCETTA government health regulator has banned Elizabeth Holmes, founder and CEO of the embattled blood testing startup Theranos, from operating a lab for at least two years, the company announced yesterday (July 8). The Centers for Medicare & Medicaid Services (CMS) also yanked the certificate for its Newark, California lab, imposed an unspecified fine, and suspended approval of Medicare and Medicaid payments for lab services, according to the statement.

“We accept full responsibility for the issues at our laboratory in Newark, California, and have already worked to undertake comprehensive remedial actions,” Holmes said in the statement. “While we are disappointed by CMS’ decision, we take these matters very seriously and are committed to fully resolving all outstanding issues with CMS and to demonstrating our dedication to the highest standards of quality and compliance.”

The Newark lab’s revocation takes effect in two months’ time, but Theranos said it would not conduct any patient testing there “until further notice.” In the meantime, the facility will be shut down and rebuilt “from the ground up,” and the company will hire new leadership and personnel, Homes said in the statement. The company said it will continue to serve ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies